机译:利妥昔单抗-CHOP免疫化学疗法治疗CD99表达和新诊断的弥漫性大B细胞淋巴瘤
Department of Internal Medicine, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Incheon, 405-760, Republic of Korea;
Department of Pathology, Ewha Womans University School of Medicine, 911-1 Mok-dong, Yangcheon-gu, Seoul, 158-710, Republic of Korea;
Department of Internal Medicine, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Incheon, 405-760, Republic of Korea;
Department of Internal Medicine, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Incheon, 405-760, Republic of Korea;
Department of Internal Medicine, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Incheon, 405-760, Republic of Korea;
Department of Internal Medicine, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Inche;
CD99; Diffuse large B-cell lymphoma; Prognosis; Immunohistochemistry;
机译:利妥昔单抗-CHOP免疫化学疗法治疗CD99表达和新诊断的弥漫性大B细胞淋巴瘤
机译:NF-Kappa B亚基C-Rel和P53突变体的核心共同抑制在用Rituximab-Chop免疫细胞治疗的弥漫性大B细胞淋巴瘤患者中的存活率显着差:International DLBCL rituximab-Chop联盟的报告
机译:利妥昔单抗-CHOP免疫化学疗法治疗的弥漫性大B细胞淋巴瘤患者中与TP53遗传状态相对应的MDM2表型和基因型谱:国际DLBCL利妥昔单抗-CHOP联合计划的报告
机译:HIP1R在B细胞亚群中的表达特征及其在弥漫性大B细胞淋巴瘤中的功能的计算机预测
机译:FGFR-2(BEK)在弥漫性大B细胞淋巴瘤中的表达与临床相关性。
机译:利妥昔单抗-CHOP免疫化学疗法治疗的弥漫性大B细胞淋巴瘤患者的MDM2表型和基因型谱分别与TP53遗传状态有关:国际DLBCL利妥昔单抗-CHOP联合计划的报告
机译:利妥昔单抗-CHOP免疫化学疗法治疗的弥漫性大型B细胞淋巴瘤患者中MTP2的表型和基因型谱与TP53遗传状态有关:国际DLBCL利妥昔单抗-CHOP联合计划的报告